论文部分内容阅读
目的:观察三氧化二砷(ATO)注射液治疗急性早幼粒细胞白血病(APL)的疗效,以及外周血白细胞和骨髓象的动态改变与临床意义。方法:对27例初诊和2例DA方案治疗复发急性早幼粒细胞白血病给予ATO注射液10mg/d静脉滴注诱导治疗,治疗过程中每2周进行骨髓检查,对白细胞>50×109/L的病人加用小剂量羟基脲化疗。统计数据以SPSS11.5系统软件进行分析。结果:29例病人经ATO诱导分化治疗26例获CR,CR率为89.7%;CR中18例出现白细胞增高,达高峰平均时间为9.2±2.4天,高峰持续时间平均为10.3±4.6天,在整个治疗过程中骨髓未出现增生受抑制的情况,骨髓异常早幼粒细胞计数显著下降(p<0.01),同时呈转化趋势,逐渐向中、晚幼粒细胞转化;并且骨髓中早幼粒细胞的下降与早幼粒细胞以下阶段细胞的上升呈明显相关性(p<0.05)。结论:常规剂量浓度ATO治疗APL诱导治疗缓解率高,副作用轻。
Objective: To observe the curative effect of Arsenic Trioxide (ATO) injection on acute promyelocytic leukemia (APL) and the dynamic change and clinical significance of peripheral blood leukocytes and bone marrow. Methods: 27 cases of newly diagnosed and 2 cases of regimen of acute promyelocytic leukemia treated with ATO injection of 10mg / d intravenous infusion of induction therapy, bone marrow examination every 2 weeks during the treatment of leukocytes> 50 × 109 / L Of patients plus a small dose of hydroxyurea chemotherapy. Statistical data SPSS11.5 system software for analysis. Results: Twenty-nine patients were treated with ATO and were differentiated into CR. The CR rate was 89.7%. In CR, 18 patients had leukocytosis with an average peak time of 9.2 ± 2.4 days and an average peak duration of 10.3 ± 4.6 days. In the whole course of treatment, there was no inhibition of proliferation of bone marrow, and the number of abnormal myelocytic cells in bone marrow decreased significantly (p <0.01), and at the same time, it was transformed into middle and late promyelocytic leukemia cells. Was significantly correlated with the increase of cells in the following stages of promyelocytic (p <0.05). CONCLUSION: APO induced by conventional dosage of ATO has high remission rate and mild side effects.